Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

249
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
249
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

223
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
223
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

14
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
14
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

18
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
18
Pericarditis III: Medical Management01:17

Pericarditis III: Medical Management

24
The primary objectives of managing pericarditis are to determine the underlying cause, provide effective therapy for treatment and symptom relief, and promptly detect signs and symptoms of cardiac tamponade. The following outlines the essential aspects of medical management for pericarditis:ObjectivesDetermine the Cause: Identifying the underlying cause of pericarditis is crucial for targeted treatment. Causes include viral infections, autoimmune diseases, post-cardiac injury syndrome, and...
24
Endocarditis III: Medical Management01:18

Endocarditis III: Medical Management

14
Infective endocarditis management involves a multifaceted approach encompassing infection prevention, lifestyle modifications, pharmacological therapy, and surgical management.Infection Prevention:Hand Hygiene: Thorough handwashing is crucial to prevent the spread of infection. Hand hygiene should be performed regularly, especially before and after using the restroom.Oral Hygiene: Good oral hygiene is essential. It includes brushing teeth immediately after waking up and before bed, flossing...
14

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Optimizing a Hematology/Oncology Curriculum for Internal Medicine Residents: A Two-Institution Modified Delphi Study.

Journal of cancer education : the official journal of the American Association for Cancer Education·2026
Same author

Elevated Neonatal Electrical Impedance Spectroscopy Measurements Are Associated With Atopic Dermatitis in High-Risk Infants.

Allergy·2026
Same author

Elevated ferritin as a companion biomarker of myeloid-driven inflammation in RNP/Sm co-positive, treatment-resistant SLE endotype.

bioRxiv : the preprint server for biology·2026
Same author

Rituximab versus cyclophosphamide for IgA vasculitis.

Arthritis & rheumatology (Hoboken, N.J.)·2026
Same author

Innovating to Improve Individualized Training in Internal Medicine Residency: Inpatient Threads and Block 2.0.

Journal of general internal medicine·2025
Same author

Protocol design for the ACTIVATE clinical trial: Exposure to vaginal microbiome in cesarean-delivered infants at high risk for allergies.

The journal of allergy and clinical immunology. Global·2025
Same journal

Senotherapeutic strategies for ovarian aging: Mechanistic insights and translational perspectives.

Current opinion in pharmacology·2026
Same journal

Chrono-immunotherapy in precision oncology: Circadian control of the tumor microenvironment and time-of-day optimization of immune checkpoint blockade.

Current opinion in pharmacology·2026
Same journal

Methotrexate: Integrating molecular pharmacology, systems toxicology, and precision rescue strategies.

Current opinion in pharmacology·2026
Same journal

Acupuncture and non-invasive neuromodulation-induced neuro-endocrine-immune changes associated with the amelioration of depression-like behaviors: A systematic review of animal studies.

Current opinion in pharmacology·2026
Same journal

Alopecia areata: Mechanisms, targeted therapies, and translational challenges.

Current opinion in pharmacology·2026
Same journal

State-dependent neurotensin modulation in the brain: From network dynamics to pharmacological opportunity.

Current opinion in pharmacology·2026
See all related articles

Related Experiment Video

Updated: Sep 2, 2025

Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis
06:59

Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis

Published on: August 26, 2025

45

New developments in treatments for systemic vasculitis.

Sarah Goglin1, Sharon A Chung2

  • 1Division of Rheumatology, Zuckerberg San Francisco General Hospital, San Francisco, CA, USA; Russell/Engleman Rheumatology Research Center, University of California, San Francisco, USA.

Current Opinion in Pharmacology
|August 3, 2022
PubMed
Summary
This summary is machine-generated.

New treatments for systemic vasculitides, like giant cell arteritis and ANCA-associated vasculitis, offer alternatives to traditional immunosuppressants. These advancements aim to reduce severe side effects and improve patient outcomes in autoimmune diseases.

More Related Videos

Author Spotlight: Utilizing Venoplasty Balloon Model in Rodents to Simulate Surgical Interventions for Deep Veins
05:44

Author Spotlight: Utilizing Venoplasty Balloon Model in Rodents to Simulate Surgical Interventions for Deep Veins

Published on: May 24, 2024

730
Osmotic Drug Delivery to Ischemic Hindlimbs and Perfusion of Vasculature with Microfil for Micro-Computed Tomography Imaging
10:50

Osmotic Drug Delivery to Ischemic Hindlimbs and Perfusion of Vasculature with Microfil for Micro-Computed Tomography Imaging

Published on: June 29, 2013

12.5K

Related Experiment Videos

Last Updated: Sep 2, 2025

Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis
06:59

Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis

Published on: August 26, 2025

45
Author Spotlight: Utilizing Venoplasty Balloon Model in Rodents to Simulate Surgical Interventions for Deep Veins
05:44

Author Spotlight: Utilizing Venoplasty Balloon Model in Rodents to Simulate Surgical Interventions for Deep Veins

Published on: May 24, 2024

730
Osmotic Drug Delivery to Ischemic Hindlimbs and Perfusion of Vasculature with Microfil for Micro-Computed Tomography Imaging
10:50

Osmotic Drug Delivery to Ischemic Hindlimbs and Perfusion of Vasculature with Microfil for Micro-Computed Tomography Imaging

Published on: June 29, 2013

12.5K

Area of Science:

  • Rheumatology and Immunology
  • Autoimmune Diseases
  • Vasculitis Treatment

Background:

  • Systemic vasculitides are rare autoimmune disorders causing significant illness and death.
  • Current primary treatments involve glucocorticoids and immunosuppressants, leading to adverse effects like toxicity and infection.
  • There is a critical need for safer and more effective therapeutic strategies.

Purpose of the Study:

  • To review recent advancements in treating giant cell arteritis (GCA) and ANCA-associated vasculitis (AAV).
  • To highlight novel therapeutic agents and strategies for managing these rare autoimmune diseases.
  • To discuss approaches for minimizing glucocorticoid exposure and associated toxicities.

Main Methods:

  • Review of recent clinical trials and therapeutic developments.
  • Focus on biologic agents for GCA and polymyalgia rheumatica (PMR).
  • Examination of plasma exchange and glucocorticoid-sparing strategies for AAV.

Main Results:

  • Emergence of effective glucocorticoid-sparing agents and alternative therapies.
  • Biologic agents show promise in treating GCA and PMR.
  • Plasma exchange and optimized glucocorticoid regimens are key for AAV management.

Conclusions:

  • Recent clinical trials offer promising new treatment avenues for systemic vasculitides.
  • Biologics and refined therapeutic strategies represent significant progress in managing GCA and AAV.
  • Minimizing glucocorticoid exposure is crucial for reducing treatment-related adverse events.